Mining and engineering novel staphylococcal lysostaphins as species-specific antibacterial agents.

Authors

Michał Bukowski, Aliaksandr Zhydzetski, Alicja Jankowska, Kinga Chlebicka, Daniel Moreno Zarta, Jakub Malerczyk, Filip Włudyka, Helena Tossavainen, Lina Antenucci, Perttu Permi, Karolina Świderska, Marcin Drąg, Benedykt Władyka

Published in

Antimicrobial agents and chemotherapy. Pages e0084526. Nov 09, 2026. Epub Nov 09, 2026.

Abstract

Antimicrobial resistance (AMR) presents a serious global healthcare challenge, with staphylococci, especially Staphylococcus aureus, being the main cause of deadly infections. Peptidoglycan hydrolases, particularly lysostaphins, are highly promising alternatives to traditional antibiotics, collectively termed enzybiotics, due to their specific lytic action against the bacterial cell wall. To thoroughly explore their therapeutic potential, we performed comprehensive genome mining of 118,127 staphylococcal and 500 closely related mammaliicoccal genomes. Ultimately, we discovered 19 unique lysostaphin sequences, divided into four distinct evolutionary clusters. By characterizing five novel lysostaphins alongside known references, we observed diverse lytic activities and species-specificities. Notably, we identified a novel lysostaphin variant from Staphylococcus simulans, Lys-Ssim, representing a previously unknown evolutionary cluster, which exhibits unmatched substrate promiscuity and an unprecedented lytic activity that extends beyond staphylococci. Additionally, structural modeling and site-directed mutagenesis revealed that peptidoglycan hydrolysis by these M23 metalloproteases depends on highly flexible conformations of the binding cleft. Using these structural insights, we successfully engineered lysostaphins with significantly improved enzyme selectivity for S. aureus while nearly eliminating activity against the skin commensal S. epidermidis. We also demonstrated the potential to engineer lysostaphins active against species other than staphylococci. Our findings show that natural staphylococcal lysostaphins are a rich, highly specialized resource for developing rationally engineered, microbiota-friendly antibacterial agents.

PMID:
43002069
Bibliographic data and abstract were imported from PubMed on 09 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.